Abionyx climbed 8% on the Paris Bourse on Monday, after being selected to share the results of its Phase 2 study in sepsis at the forthcoming American Society of Nephrology (ASN) congress.

This "late-breaking presentation" will enable the biotech to unveil the clinical data from its sepsis study, which met its primary and secondary objectives.

For the record, this trial generated robust patient data and strongly supported the decision to initiate a global pivotal study for CER-001 in the treatment of sepsis.

Two additional abstracts have been accepted for the ASN meeting: an oral presentation on CER-001 treatment in ischemia/reperfusion injury, and a poster on the effects of CER-001 in brain fog associated with acute kidney injury

The annual meeting of the American Society of Nephrology (ASN) will be held November 2-5, 2023 in Philadelphia, Pennsylvania.

Copyright (c) 2023 CercleFinance.com. All rights reserved.